BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
Total Valuation
BioAge Labs, Inc. has a market cap or net worth of $800.61M. The enterprise value is $465.75M.
Market Cap$800.61M
Enterprise Value$465.75M
Share Statistics
BioAge Labs, Inc. has 44,379,753 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44,379,753
Owned by Insiders10.17%
Owned by Institutions36.41%
Financial Efficiency
BioAge Labs, Inc.’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -33.38%.
Return on Equity (ROE)-0.30
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-33.38%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee145.08K
Profits Per Employee-1.30M
Employee Count62
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BioAge Labs, Inc. is ―. BioAge Labs, Inc.’s PEG ratio is 0.09.
PE Ratio―
PS Ratio52.85
PB Ratio1.75
Price to Fair Value1.75
Price to FCF-5.77
Price to Operating Cash Flow-7.75
PEG Ratio0.09
Income Statement
In the last 12 months, BioAge Labs, Inc. had revenue of 8.99M and earned -80.61M in profits. Earnings per share was -2.24.
Revenue8.99M
Gross Profit8.99M
Operating Income-92.78M
Pretax Income-80.61M
Net Income-80.61M
EBITDA-92.78M
Earnings Per Share (EPS)-2.24
Cash Flow
In the last 12 months, operating cash flow was -81.63M and capital expenditures -719.00K, giving a free cash flow of -82.35M billion.
Operating Cash Flow-81.63M
Free Cash Flow-82.35M
Free Cash Flow per Share-1.86
Dividends & Yields
BioAge Labs, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.68
52-Week Price Change425.95%
50-Day Moving Average19.58
200-Day Moving Average10.78
Relative Strength Index (RSI)47.78
Average Volume (3m)540.74K
Important Dates
BioAge Labs, Inc. upcoming earnings date is May 12, 2026, After Close (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateMay 12, 2026
Ex-Dividend Date―
Financial Position
BioAge Labs, Inc. as a current ratio of 14.24, with Debt / Equity ratio of 2.04%
Current Ratio14.24
Quick Ratio14.24
Debt to Market Cap0.01
Net Debt to EBITDA1.98
Interest Coverage Ratio-133.11
Taxes
In the past 12 months, BioAge Labs, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
BioAge Labs, Inc. EV to EBITDA ratio is -3.15, with an EV/FCF ratio of -3.55.
EV to Sales32.47
EV to EBITDA-3.15
EV to Free Cash Flow-3.55
EV to Operating Cash Flow-3.58
Balance Sheet
BioAge Labs, Inc. has $281.10M in cash and marketable securities with $5.56M in debt, giving a net cash position of $275.54M billion.
Cash & Marketable Securities$281.10M
Total Debt$5.56M
Net Cash$275.54M
Net Cash Per Share$6.21
Tangible Book Value Per Share$7.57
Margins
Gross margin is 99.23%, with operating margin of -1031.46%, and net profit margin of -896.11%.
Gross Margin99.23%
Operating Margin-1031.46%
Pretax Margin-896.11%
Net Profit Margin-896.11%
EBITDA Margin-1031.46%
EBIT Margin-1031.46%
Analyst Forecast
The average price target for BioAge Labs, Inc. is $47.97, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$47.97
Price Target Upside165.91% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast-1.89%